United States

Extended Release Injectable Naltrexone (Vivitrol)

"What is VIVITROL?
"VIVITROL is a prescription injectable medicine used to:
"• treat alcohol dependence. You should stop drinking before starting VIVITROL.
"• prevent relapse to opioid dependence, after opioid detoxification.
"This means that if you take opioids or opioid-containing medicines, you must stop taking them before you start receiving VIVITROL. See “What is the most important information I should know about VIVITROL?”

Likelihood That Young People with Diagnosed Mental Health Conditions Will be Put on Long Term Opioid Therapy

"Of the 1,000,453 opioid recipients (81.7%) with at least 6 months of follow-up, 51.1% were female, and the median age was 17 years (interquartile range, 16-18 years). Among these adolescents, the estimated cumulative incidence of LTOT [Long Term Opioid Therapy] after first opioid receipt was 1.1 (95% CI, 1.1-1.2) per 1000 recipients within 1 year, 3.0 (95% CI, 2.8-3.1) per 1000 recipients within 3 years, 8.2 (95% CI, 7.8-8.6) per 1000 recipients within 6 years, and 16.1 (95% CI, 14.2-18.0) per 1000 recipients within 10 years.

Likelihood That Young People with Diagnosed Mental Health Conditions Will be Put on Long Term Opioid Therapy

"In this nationwide study of commercially insured adolescents, LTOT [Long Term Opioid Therapy] was relatively uncommon. The estimated incidence of LTOT receipt was 3.0 per 1000 adolescents within 3 years of filling an initial opioid prescription. Although adolescents with a wide range of preexisting mental health conditions and treatments were modestly more likely than adolescents without those conditions or treatments to receive an initial opioid, the former had substantially higher rates of subsequent transitioning to LTOT.

The Burden of Opioid-Related Mortality in the United States

"Over the 15-year study period, 335,123 opioid-related deaths in the United States met our inclusion criteria, with an increase of 345% from 9489 in 2001 (33.3 deaths per million population) to 42,245 in 2016 (130.7 deaths per million population). By 2016, men accounted for 67.5% of all opioid-related deaths (n = 28,496), and the median (interquartile range) age at death was 40 (30-52) years.

Retail Price of Heroin in the US, Canada and the UK

According to the United Nations Office on Drugs and Crime:

In the United States in 2015 (the most recent year for which data are available), the retail price of black tar heroin ranged from $20 to $300 per gram; the retail price of South American heroin ranged from $25 to $400 per gram; and the retail price of southwest Asian heroin ranged from $120 to $300 per gram.

In Canada in 2014 (the most recent year for which data are available), the retail price of opium ranged from $43 to $55.90 per gram; and the retail price of heroin ranged from $154.80 to $300.90 per gram.

Wholesale Price of Heroin in the US and Around the World

According to the United Nations Office on Drugs and Crime:

In the United States in 2015 (the most recent year for which data are available), the wholesale price of black tar heroin ranged from $12,000 to $100,000 per kilogram; the wholesale price of South American heroin ranged from $10,000 to $100,000 per kilogram and the price of southwest Asian heroin ranged from $50,000 to $85,000 per kilogram.

In Mexico in 2015 (the most recent year for which data are available), the wholesale price of heroin was $35,000 per kilogram.

Changes in Synthetic Opioid Involvement in Overdose Deaths in the US and Involvement of Other Drugs in Combination

"Among the 42 249 opioid-related overdose deaths in 2016, 19,413 involved synthetic opioids, 17,087 involved prescription opioids, and 15,469 involved heroin. Synthetic opioid involvement in these deaths increased significantly from 3007 (14.3% of opioid-related deaths) in 2010 to 19,413 (45.9%) in 2016 (P for trend <.01). Significant increases in synthetic opioid involvement in overdose deaths involving prescription opioids, heroin, and all other illicit or psychotherapeutic drugs were found from 2010 through 2016 (Table).

Prevalence of DMS-5 Post-Traumatic Stress Disorder in the United States

"Past-year (4.7%) and lifetime (6.1%) prevalences of DSM-5 PTSD represent 10,972,986 and 14,411,005 affected U.S. adults, respectively. Broadly consistent with previous findings [3, 4, 42, 43], prevalences were higher among women and respondents aged <65 years, previously married, and with <high school education and household income <$70,000. Rates were also higher among Native American, but lower among Asian and Pacific Islander and Hispanic, versus non-Hispanic white, respondents, and lower among urban than rural residents.

Alcohol Use Disorder, Comorbidity/Co-Occurring Disorders, and Treatment

"We generally found significant associations between 12-month and lifetime AUD and other substance use disorders, major depressive disorder, bipolar I disorder, specific phobia, and antisocial and borderline PDs when we controlled for sociodemographic characteristics and other disorders. Significant associations between persistent depressive disorder, posttraumatic stress disorder, panic disorder, and generalized anxiety disorder with lifetime AUD were also observed.

Pages